TriLink BioTechnologies® Announces Manufacturing Capabilities Expansion as mRNA Manufacturing Facility Nears Completion
24.5.2023 15:10:00 EEST | Business Wire | Press release
TriLink BioTechnologies (TriLink ® ), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the expansion of its mRNA manufacturing capabilities to serve late-phase drug developers. TriLink’s construction of the new 32,000-square-foot, cGMP-grade facility solidifies its commitment to advancing the field as more mRNA-based therapeutics and vaccines enter later-stage clinical trials.
TriLink has reliably delivered GMP services to its customers since the debut of its first cGMP manufacturing facility in 2015. Built to meet the need of a rapidly growing market, the new cGMP facility is expected to contribute to the development of vital mRNA therapeutics. The building has been designed for the cGMP manufacture of mRNA-based in vivo gene editing, gene-edited cell therapies, protein replacement therapies, cancer vaccines, and infectious disease vaccines.
“The expansion of our cGMP mRNA manufacturing capabilities marks a major milestone for TriLink and our partners,” said Becky Buzzeo, Chief Commercial Officer at Maravai LifeSciences. “Drug developers will soon be able to leverage our team’s 25-plus years of industry expertise, helping to take critical therapeutics from concept to plasmid DNA through to late-phase clinical mRNA drug substance manufacturing with ease.”
Just minutes from the company’s San Diego headquarters, the new facility boasts ISO 7 cleanrooms and increased mRNA capacity (1g to >50g per batch), with comprehensive in-house analytical services also available. “Our team took great care in building and designing our new facility– it’s truly been a labor of love,” added Rob Carpenter, Vice President of Engineering at TriLink. “In addition to having access to a state-of-the-art facility, developers will also have a direct line to our experienced team to help with process optimization, scale-up, validation, and qualification capabilities.”
To learn more about TriLink’s products and services, visit trilinkbiotech.com
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is helping to realize the power and potential of mRNA. As a global leader in nucleic acid and mRNA solutions for more than 25 years, TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its proprietary CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
For more information about TriLink, visit www.trilinkbiotech.com.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
Forward-looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements related to the expectation that our expanded manufacturing capabilities will simplify and contribute to mRNA therapeutics development, our ability to attract and serve late-phase drug developers, an increase of mRNA-based therapeutics and vaccines entering later-stage clinical trials, and our ability to help to take critical therapeutics from concept through late-phase clinical mRNA drug substance manufacturing constitute forward-looking statements identified by words like “expect,” “estimate,” “may,” “soon,” “nears,” “slated,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation and uncertainties related to construction and permitting delays, availability and delays in delivery of equipment, continued validation of the safety and effectiveness of our technology, and new scientific developments and competition from other products. These and other risks and uncertainties are described in greater detail in the “Risk Factors” section of our most recent Annual Report on Form 10-K, as well as other reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward-looking statements, and therefore you should not rely upon them. These forward-looking statements reflect our current views and we do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005159/en/
Contact information
Liz Robinson, PR Account Supervisor at CG Life, lrobinson@cglife.com, 847-702-8099
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quaise Energy Closes $180 Million Series B with $35 Million Investment from Nabors Industries and Strategic Framework to Build World's First Superhot Geothermal Power Plant27.8.2026 14:05:00 EEST | Press release
Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced the final close of its Series B, raising a total of $180 million in equity financing, including a $35 million investment from Nabors Industries (NYSE: NBR), one of the world's largest land drilling contractors and a long-standing partner to Quaise. Nabors has also entered into a strategic framework agreement that supports Quaise’s mission to make superhot geothermal a commercial reality, beginning with the development of Project Obsidian, the world’s first superhot geothermal power plant. The Series B brings Quaise’s total funding to date to $280 million. “We are unlocking the most powerful clean energy source on Earth, and the Series B signals deep conviction across a wide range of investors,” said Carlos Araque, CEO and President, Quaise Energy. “Nabors is an invaluable partner as we move millimeter wave drilling to full commercial operations at Project Obsidian and beyond.” Nabors’ invest
83% of Chinese Consumers Use Quick Commerce, Offering a Glimpse into Grocery's Future27.8.2026 13:30:00 EEST | Press release
The next major shift in retail may not be happening on shelves. It is happening in the everyday grocery basket, where speed, convenience and top-up missions are reshaping how consumers buy. Quick commerce is emerging as a core engine of grocery growth, according to NIQ (NYSE: NIQ), a leading consumer intelligence company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824560517/en/ Asia is leading the quick commerce revolution, with adoption rates of 83% in China and 82% in India. NIQ's global report, The Commerce Revolution: Where East Meets West, finds that ultra-fast delivery is already mainstream across parts of Asia, offering a preview of how commerce is likely to evolve globally. The clearest signs of this shift can be seen in China and India, where quick commerce adoption has reached 83% and 82%, respectively, far exceeding the global average of 48%. By comparison, adoption stands at 34% in Europe and just 3% in No
74% of Shoppers Use AI for Discovery—NIQ Showcases What That Means for the Consumer Purchase Journey in New Report27.8.2026 13:00:00 EEST | Press release
Consumers are increasingly turning to new technologies to help navigate a more complex shopping landscape. Nearly three-quarters of shoppers now use AI for product discovery, while retail media has grown into a $184 billion global market. Together, these shifts are reshaping how products are discovered, evaluated, and ultimately purchased. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827177247/en/ AI is becoming the new gatekeeper of product discovery. NIQ has released A Tale of Two Consumers: The Polarized Mindsets Reshaping Global Consumption, a new global report in collaboration with World Data Lab showing how artificial intelligence, retail media networks, and social commerce are transforming the path to purchase and influencing which products consumers ultimately buy. The findings build on NIQ's recently released The Commerce Revolution: Where East Meets West, which identified the convergence of Eastern commerce in
Ant International Joins Hong Kong Regulators’ GenA.I. Sandbox++ to Advance Bank Liquidity Management with AI27.8.2026 13:00:00 EEST | Press release
Ant International’s Ant Bank, a digital bank based in Hong Kong, and Bettr, its inclusive embedded financial solutions provider, have been selected to participate in Hong Kong regulators’ GenA.I. Sandbox++, focusing on the liquidity risk management track. Ant Bank will leverage Ant International's Falcon Time-Series Transformer (TST) AI Model 2.0 to enhance its FX and liquidity management capabilities. The partnership will deploy granular, statistically-grounded daily forecasts, to support more precise and proactive liquidity planning for the bank's real-time treasury management — strengthening its capabilities to support a 24/7 financial ecosystem. As Hong Kong's only digital bank deeply integrated with an e-wallet, Ant Bank aims to leverage technology to provide innovative, inclusive and customer-centric digital financial services. To enhance customer experience, the bank sought to integrate AI and LLM technology to improve the accuracy of its cashflow predictions — reflecting its cu
Ant International’s R2 Enters Brazil, Bringing Embedded Credit Technology to Serve SMBs and Gig Workers27.8.2026 12:00:00 EEST | Press release
R2 today announced its expansion into Brazil, marking the company's entry into Latin America's largest economy. With the support of Ant International, a leading global digital payment, digitisation and FinAI solutions provider, R2 will partner with digital platforms across Brazil to embed working capital solutions directly into the products their merchants and gig workers already use. For digital platforms, marketplaces, payment providers, ecommerce companies, and others serving SMBs and gig workers, R2 provides a proven embedded credit technology solution that enables them to offer financing to their users without building credit operations themselves, and without taking on credit risk. The result is a new revenue stream and a stronger value proposition for their merchant base. For the businesses and workers those platforms serve, it means access to working capital based on how they actually perform, not on documentation that most of them don't have. "Brazil is a defining milestone in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom